CSL shares plunge on medical trial disappointment
Biotechnology manufacturer CSL has failed to prove the efficacy of one of its most promising drugs under development – CSL112 (apolipoprotein A-I [human]). As recently as last year the Melbourne company was testing the drug in reducing the risk of follow on adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI) or…